Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2019

Open Access 01-12-2019 | Meningioma | Research

Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis

Published in: Radiation Oncology | Issue 1/2019

Login to get access

Abstract

Background

This retrospective German and Italian multicenter analysis aimed to compare the role of normofractionated stereotactic radiotherapy (nFSRT) to CyberKnife-based hypofractionated stereotactic radiotherapy (CK-hFSRT) for skull base meningiomas.

Methods

Overall, 341 patients across three centers were treated with either nFSRT or CK-hFSRT for skull base meningioma. Treatment planning was based on computed tomography (CT) and magnetic resonance imaging (MRI) following institutional guidelines. Most nFSRT patients received 33 × 1.8 Gy, and most CK-hFSRT patients received 5 × 5 Gy. The median follow-up time was 36 months (range: 1–232 months).

Results

In the CK-hFSRT group, the 1-, 3-, and 10-year local control (LC) rates were 99.4, 96.8, and 80.3%, respectively. In the nFSRT group, the 1-, 3-, and 10-year LC rates were 100, 99, and 79.1%, respectively. There were no significant differences in LC rates between the nFSRT and CK-hFSRT groups (p = 0.56, hazard ratio = 0.76, 95% confidence interval, 0.3–1.9). In the CK-hFSRT group, only one case (0.49%) of severe toxicity (CTCAE 4.0 ≥ 3) was observed. In the nFSRT group, three cases (2.1%) of grade III toxicity were observed.

Conclusion

This analysis of pooled data from three centers showed excellent LC and low side effect rates for patients treated with CK-hFSRT or nFSRT. The efficacy, safety, and convenience of a shortened treatment period provide a compelling case for the use of CK-hFSRT in patients with moderate size skull base meningioma and provided that OAR constraints are met.
Literature
1.
Kaul D, Badakhshi H, Gevaert T, Pasemann D, Budach V, Tuleasca C, Gruen A, Prasad V, Levivier M, Kufeld M. Dosimetric comparison of different treatment modalities for stereotactic radiosurgery of meningioma. Acta Neurochir. 2015;157:559–63 discussion 563-554.PubMedCrossRef
2.
Grosu AL, Fennell JT. morbidity and mortality due to meningioma after cranial radiotherapy. Strahlenther Onkol. 2018;194:67–9.PubMedCrossRef
3.
Kaul D, Budach V, Misch M, Wiener E, Exner S, Badakhshi H. Meningioma of the skull base: long-term outcome after image-guided stereotactic radiotherapy. Cancer Radiother. 2014;18:730–5.PubMedCrossRef
4.
Kaul D, Budach V, Wurm R, Gruen A, Graaf L, Habbel P, Badakhshi H. Linac-based stereotactic radiotherapy and radiosurgery in patients with meningioma. Radiat Oncol. 2014;9:78.PubMedPubMedCentralCrossRef
5.
Conti A, Pontoriero A, Midili F, Iati G, Siragusa C, Tomasello C, La Torre D, Cardali SM, Pergolizzi S, De Renzis C. CyberKnife multisession stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for perioptic meningiomas: intermediate-term results and radiobiological considerations. Springerplus. 2015;4:37.PubMedPubMedCentralCrossRef
6.
Nutting C, Brada M, Brazil L, Sibtain A, Saran F, Westbury C, Moore A, Thomas DG, Traish D, Ashley S. Radiotherapy in the treatment of benign meningioma of the skull base. J Neurosurg. 1999;90:823–7.PubMedCrossRef
7.
O’Steen L, Amdur RJ, Morris CG, Mendenhall WM. Challenging the concept that late recurrence and death from tumor are common after fractionated radiotherapy for benign meningioma. Radiother Oncol. 2019;137:55–60.PubMedCrossRef
8.
Combs SE, Ganswindt U, Foote RL, Kondziolka D, Tonn JC. State-of-the-art treatment alternatives for base of skull meningiomas: complementing and controversial indications for neurosurgery, stereotactic and robotic based radiosurgery or modern fractionated radiation techniques. Radiat Oncol. 2012;7:226.PubMedPubMedCentralCrossRef
9.
Moustakis C, Chan MKH, Kim J, Nilsson J, Bergman A, Bichay TJ, Palazon Cano I, Cilla S, Deodato F, Doro R, et al. Treatment planning for spinal radiosurgery : a competitive multiplatform benchmark challenge. Strahlenther Onkol. 2018;194:843–54.PubMedCrossRef
10.
Conti A, Pontoriero A, Siddi F, Iati G, Cardali S, Angileri FF, Granata F, Pergolizzi S, Germano A, Tomasello F. Post-treatment edema after meningioma radiosurgery is a predictable complication. Cureus. 2016;8:e605.PubMedPubMedCentral
11.
Conti A, Pontoriero A, Salamone I, Siragusa C, Midili F, La Torre D, Calisto A, Granata F, Romanelli P, De Renzis C, Tomasello F. Protecting venous structures during radiosurgery for parasagittal meningiomas. Neurosurg Focus. 2009;27:E11.PubMedCrossRef
12.
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, et al. Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys. 2010;37:4078–101.PubMedCrossRef
13.
Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.CrossRefPubMedPubMedCentral
14.
Lee J, Sade B. The Novel “CLASS” Algorithmic Scale for Patient Selection in Meningioma Surgery. In Meningiomas. In: Lee J, editor. . London: Springer; 2009. p. 217–21.
15.
Stafford SL, Pollock BE, Foote RL, Link MJ, Gorman DA, Schomberg PJ, Leavitt JA. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2001;49:1029–37 discussion 1037-1028.PubMed
16.
Seo Y, Kim DG, Kim JW, Han JH, Chung HT, Paek SH. Long-term outcomes after gamma knife radiosurgery for benign meningioma: a single Institution's experience with 424 patients. Neurosurgery. 2018;83:1040–9.PubMedCrossRef
17.
Kim JW, Kim DG, Se YB, Kim SK, Chung HT, Paek SH, Jung HW. Gamma knife radiosurgery for Petroclival meningioma: long-term outcome and failure pattern. Stereotact Funct Neurosurg. 2017;95:209–15.PubMedCrossRef
18.
Cohen-Inbar O, Tata A, Moosa S, Lee CC, Sheehan JP. Stereotactic radiosurgery in the treatment of parasellar meningiomas: long-term volumetric evaluation. J Neurosurg. 2018;128:362–72.PubMedCrossRef
19.
Cohen-Inbar O, Lee CC, Sheehan JP. The contemporary role of stereotactic radiosurgery in the treatment of Meningiomas. Neurosurg Clin N Am. 2016;27:215–28.PubMedCrossRef
20.
Kondziolka D, Patel AD, Kano H, Flickinger JC, Lunsford LD. Long-term outcomes after gamma knife radiosurgery for Meningiomas. Am J Clin Oncol. 2016;39:453–7.PubMedCrossRef
21.
Faramand A, Kano H, Niranjan A, Johnson SA, Hassib M, Park KJ, Arai Y, Flickinger JC, Lunsford LD. Cranial nerve outcomes after primary stereotactic radiosurgery for symptomatic skull base meningiomas. J Neuro-Oncol. 2018;139:341–8.CrossRef
22.
Sheehan JP, Starke RM, Kano H, Kaufmann AM, Mathieu D, Zeiler FA, West M, Chao ST, Varma G, Chiang VL, et al. Gamma knife radiosurgery for sellar and parasellar meningiomas: a multicenter study. J Neurosurg. 2014;120:1268–77.PubMedCrossRef
23.
Combs SE, Adeberg S, Dittmar JO, Welzel T, Rieken S, Habermehl D, Huber PE, Debus J. Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiother Oncol. 2013;106:186–91.PubMedCrossRef
24.
Solda F, Wharram B, Gunapala R, Brada M. Fractionated stereotactic conformal radiotherapy for optic nerve sheath meningiomas. Clin Oncol (R Coll Radiol). 2012;24:e106–12.CrossRef
25.
Steinvorth S, Welzel G, Fuss M, Debus J, Wildermuth S, Wannenmacher M, Wenz F. Neuropsychological outcome after fractionated stereotactic radiotherapy (FSRT) for base of skull meningiomas: a prospective 1-year follow-up. Radiother Oncol. 2003;69:177–82.PubMedCrossRef
26.
Fokas E, Henzel M, Surber G, Hamm K, Engenhart-Cabillic R. Stereotactic radiation therapy for benign meningioma: long-term outcome in 318 patients. Int J Radiat Oncol Biol Phys. 2014;89:569–75.PubMedCrossRef
27.
Andrews DW, Faroozan R, Yang BP, Hudes RS, Werner-Wasik M, Kim SM, Sergott RC, Savino PJ, Shields J, Shields C, et al. Fractionated stereotactic radiotherapy for the treatment of optic nerve sheath meningiomas: preliminary observations of 33 optic nerves in 30 patients with historical comparison to observation with or without prior surgery. Neurosurgery. 2002;51:890–902 discussion 903-894.PubMed
28.
Astner ST, Theodorou M, Dobrei-Ciuchendea M, Auer F, Kopp C, Molls M, Grosu AL. Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas. Strahlenther Onkol. 2010;186:423–9.PubMedCrossRef
29.
Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–7.PubMedCrossRef
30.
Jeremic B, Pitz S. Primary optic nerve sheath meningioma: stereotactic fractionated radiation therapy as an emerging treatment of choice. Cancer. 2007;110:714–22.PubMedCrossRef
31.
Pacelli R, Cella L, Conson M, Tranfa F, Strianese D, Liuzzi R, Solla R, Farella A, Salvatore M, Bonavolonta G. Fractionated stereotactic radiation therapy for orbital optic nerve sheath meningioma - a single institution experience and a short review of the literature. J Radiat Res. 2011;52:82–7.PubMedCrossRef
32.
Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, Gnirs R, Roethke MC, Schlemmer HP, Haberkorn U. Comparison of (6)(8)Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro-Oncology. 2015;17:312–9.PubMedCrossRef
33.
Farzin M, Molls M, Kampfer S, Astner S, Schneider R, Roth K, Dobrei M, Combs S, Straube C. Optic toxicity in radiation treatment of meningioma: a retrospective study in 213 patients. J Neuro-Oncol. 2016;127:597–606.CrossRef
34.
Mozes P, Dittmar JO, Habermehl D, Tonndorf-Martini E, Hideghety K, Dittmar A, Debus J, Combs SE. Volumetric response of intracranial meningioma after photon or particle irradiation. Acta Oncol. 2017;56:431–7.PubMedCrossRef
35.
Stade F, Dittmar JO, Jakel O, Kratochwil C, Haberkorn U, Debus J, Combs SE. Influence of (68) Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy. Radiat Oncol. 2018;13:58.PubMedPubMedCentralCrossRef
36.
Combs SE, Farzin M, Boehmer J, Oehlke O, Molls M, Debus J, Grosu AL. Clinical outcome after high-precision radiotherapy for skull base meningiomas: pooled data from three large German centers for radiation oncology. Radiother Oncol. 2018;127:274–9.PubMedCrossRef
37.
Kessel KA, Fischer H, Oechnser M, Zimmer C, Meyer B, Combs SE. High-precision radiotherapy for meningiomas : long-term results and patient-reported outcome (PRO). Strahlenther Onkol. 2017;193:921–30.PubMedCrossRef
38.
Lo SS, Cho KH, Hall WA, Kossow RJ, Hernandez WL, McCollow KK, Gerbi BJ, Higgins PD, Lee CK, Dusenbery KE. Single dose versus fractionated stereotactic radiotherapy for meningiomas. Can J Neurol Sci. 2002;29:240–8.PubMedCrossRef
39.
Metellus P, Regis J, Muracciole X, Fuentes S, Dufour H, Nanni I, Chinot O, Martin PM, Grisoli F. Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy. Neurosurgery. 2005;57:873–86 discussion 873-886.PubMedCrossRef
40.
41.
Torres RC, Frighetto L, De Salles AA, Goss B, Medin P, Solberg T, Ford JM, Selch M. Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. Neurosurg Focus. 2003;14:e5.PubMedCrossRef
42.
Pollock BE, Stafford SL, Utter A, Giannini C, Schreiner SA. Stereotactic radiosurgery provides equivalent tumor control to Simpson grade 1 resection for patients with small- to medium-size meningiomas. Int J Radiat Oncol Biol Phys. 2003;55:1000–5.PubMedCrossRef
43.
Minniti G, Clarke E, Cavallo L, Osti MF, Esposito V, Cantore G, Cappabianca P, Enrici RM. Fractionated stereotactic conformal radiotherapy for large benign skull base meningiomas. Radiat Oncol. 2011;6:36.PubMedPubMedCentralCrossRef
44.
Meniai-Merzouki F, Bernier-Chastagner V, Geffrelot J, Tresch E, Lacornerie T, Coche-Dequeant B, Lartigau E, Pasquier D. Hypofractionated stereotactic radiotherapy for patients with intracranial Meningiomas: impact of radiotherapy regimen on local control. Sci Rep. 2018;8:13666.PubMedPubMedCentralCrossRef
45.
Adler JR Jr, Gibbs IC, Puataweepong P, Chang SD. Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions. Neurosurgery. 2008;62(Suppl 2):733–43.PubMed
46.
Girvigian MR, Chen JC, Rahimian J, Miller MJ, Tome M. Comparison of early complications for patients with convexity and parasagittal meningiomas treated with either stereotactic radiosurgery or fractionated stereotactic radiotherapy. Neurosurgery. 2008;62:A19–27 discussion A27–18.PubMedCrossRef
47.
Marchetti M, Bianchi S, Pinzi V, Tramacere I, Fumagalli ML, Milanesi IM, Ferroli P, Franzini A, Saini M, DiMeco F, Fariselli L. Multisession radiosurgery for Sellar and Parasellar benign Meningiomas: long-term tumor growth control and visual outcome. Neurosurgery. 2016;78:638–46.PubMedCrossRef
48.
Unger KR, Lominska CE, Chanyasulkit J, Randolph-Jackson P, White RL, Aulisi E, Jacobson J, Jean W, Gagnon GJ. Risk factors for posttreatment edema in patients treated with stereotactic radiosurgery for meningiomas. Neurosurgery. 2012;70:639–45.PubMedCrossRef
49.
Colombo F, Casentini L, Cavedon C, Scalchi P, Cora S, Francescon P. Cyberknife radiosurgery for benign meningiomas: short-term results in 199 patients. Neurosurgery. 2009;64:A7–13.PubMedCrossRef
50.
Marchetti M, Bianchi S, Milanesi I, Bergantin A, Bianchi L, Broggi G, Fariselli L. Multisession radiosurgery for optic nerve sheath meningiomas--an effective option: preliminary results of a single-center experience. Neurosurgery. 2011;69:1116–22 discussion 1122-1113.PubMed
51.
Romanelli P, Bianchi L, Muacevic A, Beltramo G. Staged image guided robotic radiosurgery for optic nerve sheath meningiomas. Comput Aided Surg. 2011;16:257–66.PubMedCrossRef
52.
Romanelli P, Wowra B, Muacevic A. Multisession CyberKnife radiosurgery for optic nerve sheath meningiomas. Neurosurg Focus. 2007;23:E11.PubMedCrossRef
53.
Marchetti M, Conti A, Beltramo G, Pinzi V, Pontoriero A, Tramacere I, Senger C, Pergolizzi S, Fariselli L. Multisession radiosurgery for perioptic meningiomas: medium-to-long term results from a CyberKnife cooperative study. J Neuro-Oncol. 2019;143:597–604.CrossRef
54.
Adeberg S, Welzel T, Rieken S, Debus J, Combs SE. Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM). Radiat Oncol. 2011;6:117.PubMedPubMedCentralCrossRef
Metadata
Title
Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis
Publication date
01-12-2019
Published in
Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-019-1397-7

Other articles of this Issue 1/2019

Radiation Oncology 1/2019 Go to the issue

Research

Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy

Research

Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience

Research

Integrative assessment of brain and bone invasion in meningioma patients

Research

Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy

Research

A phase I/II radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal Cancer

Research

Quality assurance of non-coplanar, volumetric-modulated arc therapy employing a C-arm linear accelerator, featuring continuous patient couch rotation